- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02679664
StAtins for Venous Event Reduction in Patients With Venous Thromboembolism Pilot Study (SAVER)
StAtins for Venous Event Reduction in Patients With Venous Thromboembolism: A Pilot Study Assessing Feasibility of an RCT to Evaluate if Generic Rosuvastatin Reduces the Risk of Recurrent VTE in Patients With Symptomatic Major VTE.
The SAVER pilot is a randomized, open-label pilot study to determine the feasibility of recruitment. In addition to feasibility data, the investigators will carefully collect clinical data to determine if rosuvastatin can reduce post-thrombotic syndrome (PTS) in venous thromboembolism (VTE) patients.
Eligible consenting patients who developed acute, symptomatic, and objectively confirmed proximal leg deep vein thrombosis (DVT) and/or PE will be randomized and equally allocated to 2 trial arms, either the treatment group (rosuvastatin tablet (20 mg/day) or the control group (usual care). The pilot trial consists of up to 4 study contacts over 6 months: screening, randomization, telephone follow-up (90 days), and final study visit (180 days).
Study Overview
Detailed Description
The SAVER pilot is a randomized, open-label pilot study to determine the feasibility of recruitment. In addition to feasibility data, the investigators will carefully collect clinical data to determine if rosuvastatin can reduce post-thrombotic syndrome (PTS) in venous thromboembolism (VTE) patients.
- SCREENING: Research coordinators at each pilot site will screen patients for eligibility and will complete detailed logs of all patients meeting inclusion (both enrolled and excluded). After providing informed consent, eligibility will be confirmed by the following tests : a lipid profile, A1C test/ CBC, transaminase (ALT) levels, Creatinine and pregnancy test (if a female of child bearing potential). Consenting participants who (following screening) do not meet eligibility criteria will be followed up to establish feasibility outcomes.
- RANDOMIZATION: Randomization will be conducted using an Interactive Web based Randomization System in a 1:1 ratio for treatment (20mg rosuvastatin od) or control (no study drug).
- STUDY DRUG DISPENSING: Participants randomized to the treatment arm will be dispensed x 200 20mg tablets of rosuvastatin along with a medication diary.They will be educated on study drug dosing regimen (20mg tablet od), how to complete their medication diary and on the possible side-effects of rosuvastatin. They will be advised to contact either the study coordinator, investigator or go directly to the emergency department should they experience any symptoms in particular anything muscle related.
BASELINE. Assessments include;
- Demographic data;
- Concomitant medications (antiplatelet, anti-inflammatories, anticoagulation);
- Type of index VTE;
- PTS Villalta leg assessment conducted by both the participant (Patient Reported Villalta [PRV] questionnaire) and a qualified blinded independent observer (The Villalta scale is the most extensively validated tool and is recommended by the ISTH) - (Primary Outcome);
- Risk factors for recurrent VTE, bleeding and arterial vascular events;
- Medical history including prior VTE, Arterial disease, Liver disease and Glucose Intolerance.
90 DAY FOLLOW UP [Treatment arm only]: Participants randomized to treatment will be followed up via telephone or email at 90 days (+/- 21 days);
Participants will be asked questions to screen for;
- Study outcomes: Suspected VTE, Arterial, Bleeding and/ or Muscle Events Patients who report any unexplained muscle symptoms will be asked to have their Creatine kinase (CK) levels tested within 2 weeks of reporting the symptoms. Study drug will be discontinued if CK levels are markedly elevated (> 10 x ULN).;
- Study Drug compliance
- Adverse events.
- Concomitant medication will be reviewed in case of any contraindications. Changes or additions in concomitant anticoagulation therapy, anti-platelet or anti - inflammatory medication will also be recorded.
- Study coordinators will log all follow up contact attempts.
FINAL STUDY VISIT (180 days (+/- 21 days): All study participants will be asked to attend an in person study visit at 180 days (+/-21) for;
- Follow-up of study outcomes; VTE, Arterial, Bleeding and Muscle events;
- Study drug compliance;
- Relevant (S)AE(s).
- Repeat PTS leg assessment (using the Villalta scale) both by a qualified independent observer and the participant (Primary outcome);
- Study drug compliance: Medication Diaries and used medication bottles will be collected by the study coordinator. Coordinator will perform a pill count and reconcile with the participants medication diary. Coordinator will also ask participant reasons for any missed doses.
ADJUDICATION OF STUDY OUTCOMES: All Bleeding, VTE and Arterial Suspected Events as well as deaths will be recorded on a suspected event CRF along with any diagnostic imaging/ tests and will trigger a more in-depth evaluation, and review by an independent adjudication committee.
ADVERSE EVENTS: AEs will be elicited, monitored and recorded throughout the study.
All events meeting the definition of an SAE (as per ICH-GCP) must be reported to the SAVER Trial Office in Ottawa, Canada within 24 h of awareness.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada
- Nova Scotia Health Authority
-
-
Ontario
-
Hamilton, Ontario, Canada
- Hamilton Health Sciences Corporation
-
London, Ontario, Canada
- Lawson Health Research Institute, London Health Sciences Centre
-
Ottawa, Ontario, Canada
- Ottawa Hospital
-
-
Quebec
-
Montreal, Quebec, Canada
- Sir Mortimer B. Davis Jewish General Hospital
-
-
-
-
-
Grålum, Norway
- Østfold Hospital Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1. Symptomatic objectively confirmed proximal leg DVT (above the trifurcation of the popliteal vein) and/or PE (segmental or greater) diagnosed in the last 30 days.
Exclusion Criteria:
- Unable or unwilling to provide written informed consent
- ≤ 18 years of age
- Currently prescribed a statin
A medical history or current diagnosis of any of the following:
- Abdominal aortic aneurysm,
- Peripheral arterial disease,
- Stroke,
- Transient ischemic attack (TIA),
- Myocardial infarction (MI),
- Acute coronary syndromes,
- Stable angina,
- Coronary or other arterial revascularization
- LDL-C >4.91 mmol/L
- LDL-C between 1.81mmol/L to 4.9mmol/L AND 10 ASCVD risk score >10%
- Diabetes mellitus or pre-diabetes
Contraindication to rosuvastatin;
- Hypersensitivity or intolerance to statins;
- History of muscle disorders or statin-related muscle pain;
- Liver disease (active liver disease or unexplained elevations of serum transaminases exceeding 3 times the upper limit of normal);
- Chronic kidney disease (Creatinine clearance < 30ml/min)
- Currently pregnant or breast feeding;
- Taking cyclosporine.
- Life expectancy less than 3 months, as judged by the investigator
- Unstable medical or psychological condition that would interfere with trial participation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Treatment group
20 mg tablet of rosuvastatin PO once-a-day starting at the time of randomization until the completion of follow-up at 6 months.
|
20 mg tablet of rosuvastatin
Other Names:
|
NO_INTERVENTION: Control group
Standard medical care only.
No rosuvastatin group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants recruited per center per month - [Study Feasibility]
Time Frame: 3 years
|
Study feasibility as indicated by the number of participants recruited per center per month.
|
3 years
|
Incidence of PTS
Time Frame: 180 days (+/- 21 days)
|
Incidence of post thrombotic syndrome (PTS), as measured by the Villalta scale at 6 months by both an 'Blinded Independent Assessor' and self reported by the participant.
|
180 days (+/- 21 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Symptomatic recurrent major VTE
Time Frame: 180 days (+/- 21 days)
|
Symptomatic recurrent major VTE (proximal DVT or segmental or larger PE) in patients taking generic rosuvastatin (full trial primary outcome).
Coordinators will submit a report to the independent adjudication committee for participants that undergo investigation for suspected recurrent VTE during the study.
|
180 days (+/- 21 days)
|
Components of major VTE
Time Frame: 180 days (+/- 21 days)
|
|
180 days (+/- 21 days)
|
Non-major VTE
Time Frame: 180 days (+/- 21 days)
|
|
180 days (+/- 21 days)
|
Arterial Vascular Events
Time Frame: 180 days (+/- 21 days)
|
At the 3-month call and 6-month visit the research coordinator will follow an interview script to screen for inter-current suspected arterial events. Any reported potential arterial events will trigger a more in-depth evaluation.
|
180 days (+/- 21 days)
|
All-cause mortality
Time Frame: 180 days (+/- 21 days)
|
All-cause mortality
|
180 days (+/- 21 days)
|
Bleeding
Time Frame: 180 days (+/- 21 days)
|
At each follow-up visit the research coordinator will follow an interview script to screen for suspected major and clinically relevant non-major bleeding events.
Suspected bleeding that lasts more than 10 minutes, required intervention to control or for which the patient sought medical attention will be adjudicated by an independent committee using ISTH bleeding criteria.
|
180 days (+/- 21 days)
|
Muscle Toxicity
Time Frame: 180 days (+/- 21 days)
|
Participants reporting symptoms of muscle toxicity will have their CK levels tested for safety.
Study drug will be discontinued if CK levels are markedly elevated (>10 x ULN)
|
180 days (+/- 21 days)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Marc Rodger, M.D., Ottawa Hospital Research Institute
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Embolism and Thrombosis
- Thromboembolism
- Venous Thromboembolism
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Rosuvastatin Calcium
Other Study ID Numbers
- 20160047-01H
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Venous Thromboembolism
-
BayerWithdrawnTotal Hip Replacement | Total Knee Replacement | Prophylaxis, Thromboembolism, Venous
-
University Hospital, BrestRecruitingVenous Thromboembolism (VTE)France
-
University of ArizonaRecruitingPediatric Venous ThromboembolismUnited States
-
National Taiwan University HospitalUnknownDeep Venous ThromboembolismTaiwan
-
Ya-Wei XuFirst Affiliated Hospital, Sun Yat-Sen University; Nanfang Hospital of Southern...RecruitingVenous Thromboembolism (VTE)China
-
Bristol-Myers SquibbCompletedVenous Thromboembolism (VTE)United States
-
BayerCompletedTreatment of Venous ThromboembolismJapan
-
Azidus BrasilUnknownPrevention of Venous ThromboembolismBrazil
-
Fadoi Foundation, ItalyCompletedPrevention of Venous ThromboembolismItaly
-
Fadoi Foundation, ItalyUniversity Of PerugiaCompletedPrevention of Venous ThromboembolismItaly
Clinical Trials on Rosuvastatin
-
AstraZenecaCompletedDyslipidemia | Kidney DiseaseUnited States, Puerto Rico
-
Yuhan CorporationCompletedHypertension | HyperlipidemiaKorea, Republic of
-
Kobe UniversityCompletedCoronary Artery Disease Progression
-
National Institute of Diabetes and Digestive and...National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Cancer... and other collaboratorsRecruitingCirrhosis | Cirrhosis, Liver | Cirrhosis Due to Hepatitis B | Cirrhosis Due to Hepatitis C | Cirrhosis Early | Cirrhosis Advanced | Cirrhosis Infectious | Cirrhosis Alcoholic | Cirrhosis, Biliary | Cirrhosis Cryptogenic | Cirrhosis Due to Primary Sclerosing CholangitisUnited States
-
Gachon University Gil Medical CenterDaewoong Pharmaceutical Co. LTD.UnknownCoronary Artery DiseaseKorea, Republic of
-
Alvogen KoreaCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Hanmi Pharmaceutical Company LimitedUnknownHealthyKorea, Republic of
-
Organon and CoCompleted
-
IlDong Pharmaceutical Co LtdUnknownHypertension | HyperlipidemiaKorea, Republic of